Rod Humerickhouse, MD, PhD at Abbvie Pharmaceuticals highlights the positive long-term follow-up data showing patients with chronic lymphocytic leukemia (CLL) taking venetoclax in combination with rituximab (for relapsed CLL) or obinutuzumab (newly diagnosed CLL) had high response rates – even two to four years following treatment.
The data was presented at the American Society of Hematology Annual Meeting in Orlando, Florida.
CLL is a rare blood cancer in which there is a build-up of lymphocytes in bone marrow, lymph nodes and blood. In the United States, an estimated 20,000 new cases of CLL will be diagnosed in 2019. The disease is considered treatable, but relapse is very common.
Venclexta is a B-cell lymphoma-2 (BCL-2) protein inhibitor. BCL-2 prevents apoptosis of cancer cells.
To learn more about CLL and other rare cancers, visit checkrare.com/diseases/rare-cancers/
